Amneal today announced the creation of Amneal Biosciences, a wholly-owned subsidiary of Amneal Pharmaceuticals LLC.
Bridgeater, New Jersey (USA): Amneal today announced the creation of Amneal Biosciences, a wholly-owned subsidiary of Amneal Pharmaceuticals LLC. Amneal Biosciences will focus exclusively on the commercialization of high-barrier-to-entry generic and specialty pharmaceuticals such as injectables, oncologics and biosimilars to healthcare providers globally.
“Having a dedicated company focused on the unique needs and logistics of this market segment allows Amneal to guarantee the same level of quality and service to healthcare institutions and professionals that we deliver to our existing retail customers,” explains Amneal co-CEO and Chairman Chirag Patel. “Amneal has a robust pipeline of both small-molecule injectable generics as well as biosimilars, and we expect to bring the first of these to market in early 2016. Our experienced Amneal Biosciences team provides the high degree of expertise these specialty products require.”
Heading Amneal Biosciences as President is pharmacy veteran Charles Lucarelli, MS, RPh. Charles joined Amneal in March of this year after a 37-year career at Memorial Sloan Kettering Cancer Center, including 25 years as Director of Pharmacy. In this position, Mr. Lucarelli took direct responsibility for the pharmacy department and its regional sites and was accountable for inpatient/outpatient pharmaceutical services, clinical services, and hospital-wide investigational drug and research services. Charles was a co-investigator on numerous drug studies at Memorial Sloan Kettering. He has authored numerous articles in addition to the book “Herb Drug Interactions in Oncology” and is an internationally known speaker.
“It is an honor to serve as President of Amneal Biosciences and lead this talented group of professionals at such a pivotal time in our company’s evolution,” said Mr. Lucarelli. “Our robust product pipeline will bring the Amneal legacy of quality and customer service to a segment in need of therapeutic affordability and reliable supply.”